To address these limitations, NPs have been proposed as delivery vehicles for STING agonists, as they can increase stability, prolong blood circulation time, enhance tumor targeting, and promote intracellular uptake thereby maximizing the antitumor immune effect and reducing adverse effects.18 The gene discussed is STING1; the disease is neoplasm.